达嘉维康（301126）(301126.SZ)公告，公司董事钟雪松先生计划在2025年9月1日至2025年11月30日以集 中竞价或大宗交易的方式减持股份数量不超过350万股(占公司总股本的1.70%)。 ...

每经AI快讯，8月8日，达嘉维康公告，公司董事钟雪松计划自2025年9月1日至2025年11月30日期间， 通过集中竞价或大宗交易方式减持不超过350万股，占公司总股本的比例不超过1.70%。钟雪松当前持 有公司1928.84万股，占公司总股本的9.39%。此次减持的原因是出于个人资金需求，且钟雪松已严格履 行此前的股份锁定及减持承诺。 ...

智通财经APP讯，达嘉维康(301126.SZ)公告，公司董事钟雪松先生计划在2025年9月1日至2025年11月30 日以集中竞价或大宗交易的方式减持股份数量不超过350万股(占公司总股本的1.70%)。 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2025-052 湖南达嘉维康医药产业股份有限公司 关于持股 5%以上股东、董事减持股份的预披露公告 公司持股 5%以上股东、董事钟雪松保证向本公司提供的信息真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有公司股份19,288,356股（占公司总股本9.39%）的董事钟雪松先生计划在本 公告披露之日起15个交易日后的3个月内（即2025年9月1日至2025年11月30日）以集 中竞价或大宗交易的方式减持股份数量不超过3,500,000股（占公司总股本的1.70%）。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"或"达嘉维康"）于 近日收到持股5%以上股东、董事钟雪松先生出具的《关于股份减持计划的告知函》， 现将有关情况公告如下： 一、股东基本情况 | 股东名称 | 持有股份的总数量（股） | 占公司总股本的比例 | | --- | --- | --- | | 钟雪松 | 19,288,356 | 9.39% | 三、本次计划减持股东的承诺及其履行情况 公司董 ...

Group 1 - The assisted reproductive industry is experiencing a rebound, with significant stock price increases for several companies [1] - Lideman's stock rose over 18%, indicating strong market interest and potential recovery in the sector [1] - Other companies such as Nanmo Bio, Mailande, and Guangshengtang also saw notable gains, with increases of over 15%, 14%, and additional follow-up gains from other firms [1]

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the 31 listed pharmaceutical companies, 28 have active secretaries, with the age distribution showing that 57% are between 40-50 years old, 11% are over 50, and 32% are 40 or younger [1] - The educational background of secretaries indicates that 50% hold a bachelor's degree, 46% have a master's degree, and only 4% possess a doctoral degree, with only one secretary having a PhD [1] Group 2 - The average annual salary of secretaries in A-share pharmaceutical companies is 726,500 yuan, with 43% earning below 500,000 yuan, 36% between 500,000-1 million yuan, 18% between 1-2 million yuan, and 3% above 2 million yuan [2] - The top three highest-paid secretaries are from Shanghai Pharmaceuticals, Run Da Medical, and China National Pharmaceutical Group, with salaries of 2.0373 million yuan, 1.6242 million yuan, and 1.2 million yuan respectively [2] - The largest salary decrease was observed for Wang Lei from Renmin Tongtai, with a year-on-year decline of 60.61%, while Zhang Yufeng from Zhejiang Zhenyuan experienced the largest increase at 212.33% [2]

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the 31 listed pharmaceutical companies, 28 have active secretaries, with the age distribution showing that 57% are between 40-50 years old, 11% are over 50, and 32% are 40 or younger [1] - The educational background of secretaries indicates that 50% hold a bachelor's degree, 46% have a master's degree, and only 4% possess a doctoral degree, with only one secretary having a PhD [1] Group 2 - The average annual salary of secretaries in A-share pharmaceutical companies is 726,500 yuan, with 43% earning below 500,000 yuan, 36% between 500,000-1 million yuan, 18% between 1 million-2 million yuan, and 3% earning over 2 million yuan [2] - The top three highest-paid secretaries are Zhong Tao from Shanghai Pharmaceuticals with 2.0373 million yuan, Zhang Chengxu from Run Da Medical with 1.6242 million yuan, and Luo Lichun from China National Pharmaceutical with 1.2 million yuan [2] - The largest salary decrease was observed for Wang Lei from Renmin Tongtai, with a year-on-year decline of 60.61%, while Zhang Yufeng from Zhejiang Zhenyuan experienced the largest increase at 212.33% [2]

Core Viewpoint - The company is actively exploring collaborations with major universities and hospitals to focus on the development of products and technologies in regenerative medicine for disease diagnosis and treatment [1] Group 1 - The company has stated that it will fulfill its information disclosure obligations in a timely manner if there are significant developments [1] - The subsidiary, Jiacheng Hospital, is actively pursuing the application for human assisted reproductive license qualifications [1] - The high barriers to assisted reproductive technology, along with the lengthy licensing application process and strict approval standards, create uncertainty regarding the company's future in the assisted reproductive business [1]

Group 1 - The company, Dajia Weikang, currently produces and sells several antibiotic products including Amoxicillin capsules, Ampicillin capsules, Azithromycin granules, Norfloxacin capsules, and Moxifloxacin tablets [1]

证券日报网讯达嘉维康8月7日在互动平台回答投资者提问时表示，截至2025年7月31日，公司股东人数 为21453户。 （文章来源：证券日报） ...